NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks.
Last week the Nordic healthcare stocks fell 3.1%, while the Danish healthcare stocks had a 0.7% decline. Cessatech outlined its key priorities for the rest of 2024, Genmab received price targets, and CS Medica fell 17% after more than doubling. The Danish biotech stocks have on average increased 41% year-to-date.
9 of the 22 Danish biotech companies had a positive share price development the past week and 11 companies have had a positive share price performance year-to-date. Gubra is the best-performing Danish healthcare stock year-to-date with a 433% return and European Institute of Science AB was the best Nordic healthcare investment last week. 5 Danish healthcare stocks with +100% YTD return.
Danish company news
No news the past week
No news the past week
No news the past week
Key Cessatech priorities for the rest of the year (Link)
CS MEDICA’s Subsidiary, CANNORDIC, Signs Distributor Partnership with PHARMALINK (Link)
CS MEDICA’s View of the Evolving European CBD Market (Link)
Curasight issues warrants as part of long-term incentive program (Link)
No news the past week
No news the past week
No news the past week
No news the past week
Jyske Bank lowered their price target from DKK 2,850 to DKK 2,600 and Carnegie from DKK 2,720 to DKK 2,760
No news the past week
No news the past week
No news the past week
No news the past week
No news the past week
No news the past week
No news the past week
No news the past week
Zealand Pharma Appoints Eric Cox as Chief Commercial Officer
No news the past week
No news the past week
Share price development – Danish stocks
On average, the Danish biotech and healthcare stocks delivered a poor performance with a return of -0.7%. Biosergen became the best-performing stock without any news to report. Cessatech also performed well following communication of their key priorities in 2024. Furthermore, Genmab got updated price targets, and CS Medica fell 17% although they signed a new distribution agreement with PHARMALINK. However, it should be noted that CS Medica is still up more than 100% in the past month.
The best stock year-to-date is Gubra followed by Pila Pharma with 433% and 309% increases respectively after the first 6 months of trading. CS Medica, Zealand Pharma, and Acarix have also made a +136% to 164% return year-to-date. Overall the Danish biotech and healthcare stocks are in positive territory this year with a year-to-date return of 41%. In other words, it has had a stellar performance.
Overview of share price development the past week, year-to-date, and the last twelve months
Nordic Biotech & Healthcare Developments
In the past week, the all-Nordic index Kapital Partner Nordic Healthcare Index (KPHC) fell 3.1% to 68,86. The index has had a strong performance since the end of April and it has now surpassed the KPNGX index. In the past 12 months, the KPHC index has significantly underperformed relative to large caps, while the venture/small cap Kapital Partner Nordic Growth Exchanges index (KPNGX) has followed the KPHC index’s downward trajectory down around 10%.
The index development for the KPHC index the past year
53-87% in weekly return for the Nordic healthcare stocks
European Institute of Science AB (87%) share price rose following news of a reverse acquisition of Apotek365.
Immunovia (67%) is focused on molecular diagnostics, where the business focuses on driving the development and change of current working methods for diagnosing complex cancers and immune diseases. The vision is to establish blood-based tests to be able to identify different types of pancreatic cancer at an early stage. The share price rose following of significant improvements in their pipeline (Link).
Alzinova (53%) specializes in the therapeutic treatment of Alzheimer’s and conducts research and development of peptides that are further developed as vaccines. In addition, the company also develops various research tools in the work area. The largest operations are in the Nordic market.
Sources: Refinitiv Eikon, Cision, Nordnet & company websites.
